Med-X

Med-X Secures Coveted OMRI Listing for Nature-Cide All-Purpose Commercial Concentrate to Allow for Use in Certified Organic Food Processing Facilities

Med-X Secures Coveted OMRI Listing for Nature-Cide All-Purpose Commercial Concentrate to Allow for Use in Certified Organic Food Processing Facilities

Leading Organic Trade Organization Lists Nature-Cide All-Purpose Commercial Concentrate as Allowed for the Use in Accordance with the National Organic Program (NOP) Standards for use Cases in Certified Organic Food Processing and Handling Facilities

LOS ANGELES – November 7, 2024 -- Med-X, Inc., a leading innovator of all-natural green scene solutions addressing the pest control, health and wellness markets, today announced that the Company’s Nature-Cide All-Purpose Commercial Concentrate Insecticide has secured the widely coveted designation as an OMRI® Listed product.

The Organic Materials Review Institute (OMRI) is a nonprofit organization that provides independent reviews of products intended for several use cases including use in certified organic food processing and handling. To be listed by OMRI, a pesticide product must meet strict standards for organic processing outlined by USDA National Organic Program (NOP). With the designation as an OMRI Listed Product, Nature-Cide All-Purpose Commercial Concentrate, is now one of 12 botanical pesticide products that is allowed for use in certified organic food processing and handling facilities meeting the USDA National Organic Program standards.

A white bottle with a labelDescription automatically generated

Nature-Cide All-Purpose Commercial Concentrate has been designated as “Allowed With Restrictions” carrying the following statement: For use as a pesticide in post-harvest handling of raw agricultural commodities only in conjunction with the facility pest management practices provided for in paragraphs 205.271(a) and (b) and only if those practices are not effective to prevent or control pests alone.

Matthew Mills, Chief Executive Officer of Med-X, stated: “After several years of requests from industry professionals, we are incredibly humbled to have achieved the coveted OMRI listing for one of our flagship Nature-Cide products. Pest management professionals operating in USDA certified organic facilities rely on OMRI to assure that the products they use meet the strict OMRI listing requirements, knowing that they use ingredients and formulations that are allowed under the NOP standards.

“This OMRI listing opens up a whole new market for Med-X, providing a safer and highly effective solution to pest management professionals working with a limited set of permissible tools to do their job, all while concurrently making it easier for pest management professionals to find the product and have the information and confidence that it can be used in organic facilities when needed.

“The pest control solutions for organic use market was valued at $2.4 billion in 2023 and taken together, we continue to see significant global sales momentum with our partner network for our Nature-Cide product line, addressing an urgent need for all-natural products that can be safely used in organic or sensitive industries such as agriculture and hospitality,” concluded Mills.

About Med-X, Inc.

Med-X, Inc. is a leading innovator of biological pest control solutions addressing both consumer and professional markets globally. Nature-Cide - the Company's flagship product line - is a safer, all-natural alternative to conventional chemical products, formulated to kill or repel a wide variety of pests. Med-X's comprehensive go-to-market strategy includes leveraging strategic partnerships alongside an integrated e-commerce, brick and mortar and on-site services presence in key markets. For more information, please visit our website at www.medx-rx.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sale of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 of the Securities Act. This press release may contain forward-looking statements regarding projected business performance, operating results, financial condition, and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events.

Investor Relations Contact

Lucas Zimmerman

Managing Director

MZ Group - MZ North America

+1 (262) 357-2918

MXRX@mzgroup.us

www.mzgroup.us

‍

FAQs

Why invest in startups?

Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.

How much can I invest?

Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.

How do I calculate my net worth?

To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.

What are the tax implications of an equity crowdfunding investment?

We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.

Who can invest in a Regulation CF Offering?

Individuals over 18 years of age can invest.

What do I need to know about early-stage investing? Are these investments risky?

There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.

When will I get my investment back?

The Common Stock (the "Shares") of Med-X (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.

Can I sell my shares?

Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.

Exceptions to limitations on selling shares during the one-year lockup period:

In the event of death, divorce, or similar circumstance, shares can be transferred to:

• The company that issued the securities

• An accredited investor

• A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)

What happens if a company does not reach their funding target?

If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.

How can I learn more about a company's offering?

All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.

What if I change my mind about investing?

You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: investorrelations@medx-rx.com

How do I keep up with how the company is doing?

At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.

Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.

Submission received! Check your inbox for the Med-X updates.

Med-X Secures Coveted OMRI Listing for Nature-Cide All-Purpose Commercial Concentrate to Allow for Use in Certified Organic Food Processing Facilities

NASDAQ Here We Come. Meet MXRX.

Sign Up For Company Updates

FAQs

Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.